Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
DAHLIA study of datopotamab deruxtecan in HR-positive/HER2-negative unresectable or recurrent breast cancer in Japan
jRCT1031250721Recruiting
- Sponsor
- Daiichi Sankyo Co., Ltd.
- Start
- Feb 2026
- Modality
- Cytotoxic ADCs → Antibody-Drug Conjugates (ADCs) → Antibody Conjugates → Antibody-Based Therapeutics, Monoclonal Antibodies → Antibody-Based Therapeutics, Small Molecules
- Countries
- 1
01
Overview
Open-label, single-arm trial of datopotamab deruxtecan in breast cancer, sponsored by Daiichi Sankyo Co., Ltd. Primary endpoint: Real-world progression-free survival. Started Feb 2026; status: recruiting.
02
Drugs
datopotamab deruxtecan
03
Conditions
breast cancer
Beyond the preview
Go deeper on jRCT1031250721.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCT1031250721.